NCT lookup
Pull any trial record directly from ClinicalTrials.gov.
Long-term Study of Safety and Efficacy of Roflumilast in Japanese Patients With Bronchial Asthma (20 to 71 y) (APTA-2217-07).
Long-term Study of Safety and Efficacy of Roflumilast in Japanese Patients With Bronchial Asthma (20 to 71 y) (APTA-2217-07).
CompletedPhase 3
Sponsor: AstraZeneca
Conditions: Bronchial Asthma
Interventions: Roflumilast
Countries: Japan
The aim of this long-term study is to investigate the effect of roflumilast (APTA-2217) on the long-term safety in patients with asthma, who completed the 24-week evaluation of study APTA-2217-05. Roflumilast will be administered orally once daily. The present study consists of a 28 weeks treatment period, and is the extension of the 24-week study APTA-2217-05 (registered study). The study will provide further long-term safety and efficacy data of roflumilast.
Eligibility overview
Sex: ALL
Age: 20 Years to 71 Years
Healthy volunteers: No
Study type: INTERVENTIONAL
Eligibility criteria
Main inclusion criteria: * Patients with asthma disease * Written informed consent * Patients who completed the 24-week evaluation of study APTA-2217-05 Main exclusion criteria: * % FEV1.0 \< 60% at both 18 weeks and 24 weeks measurements during APTA-2217-05 * Patients with poorly controlled asthma between informed consent day and study starting day: need for oral or intravenous steroid therapy, hospitalization or any emergency visit, PEF value worsened for 2 or more consecutive days * Serious diseases
Locations (1)
- Osaka, Japan